

# 5-Hydroxytryptamine Receptor 2B Growth and Restrain Factors Analysis By 2022

PUNE, MAHARASHTRA, INDIA, April 12, 2018 /EINPresswire.com/ -- 5-Hydroxytryptamine Receptor 2B

## Summary

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report 5-Hydroxytryptamine Receptor 2B - Pipeline Review, H1 2017, outlays comprehensive information on the 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.



Healthcare

Furthermore, this report also reviews key players involved in 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Click here for sample report @ <http://www.wiseguyreports.com/sample-request/1510546-5-hydroxytryptamine-receptor-2b-5-ht2b-or-serotonin-receptor-2b-or>

## Scope of The Report

- The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B)
- The report reviews 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

## Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Overview

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - Companies

Involved in Therapeutics Development

AnaMar AB

Astellas Pharma Inc

Biofrontera AG

.Continued

For Detailed Reading Please visit @ <https://www.wiseguyreports.com/reports/1510546-5-hydroxytryptamine-receptor-2b-5-ht2b-or-serotonin-receptor-2b-or>

## About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Norah Trent

WiseGuy Research Consultants Pvt. Ltd.

+1 646 845 9349 / +44 208 133 9349

email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the

company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.